287 related articles for article (PubMed ID: 25999749)
1. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.
Dranitsaris G; Yu B; King J; Kaura S; Zhang A
Clinicoecon Outcomes Res; 2015; 7():249-56. PubMed ID: 25999749
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
3. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
4. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Benedict A; Cameron DA; Corson H; Jones SE
Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
[TBL] [Abstract][Full Text] [Related]
5. Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis.
Force RW; Pugmire BA; Culbertson VL
Am Health Drug Benefits; 2010 Jul; 3(4):276-84. PubMed ID: 25126321
[TBL] [Abstract][Full Text] [Related]
6. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
[TBL] [Abstract][Full Text] [Related]
7. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.
Lazzaro C; Bordonaro R; Cognetti F; Fabi A; De Placido S; Arpino G; Marchetti P; Botticelli A; Pronzato P; Martelli E
Clinicoecon Outcomes Res; 2013; 5():125-35. PubMed ID: 23610525
[TBL] [Abstract][Full Text] [Related]
8. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
He F; Liu J; Shen X; Wang Z; Li Q; Li G
Ann Pharmacother; 2022 Aug; 56(8):898-909. PubMed ID: 34963337
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y
Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.
Di Costanzo F; Gasperoni S; Rotella V; Di Costanzo F
Onco Targets Ther; 2009 Feb; 2():179-88. PubMed ID: 20616905
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
12. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
13. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.
Lei L; Chen R; Fan L; Zheng W; Wang X
Ann Palliat Med; 2022 Jul; 11(7):2382-2394. PubMed ID: 35927773
[TBL] [Abstract][Full Text] [Related]
15. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY
Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J
Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.
Vishnu P; Roy V
Breast Cancer (Auckl); 2011; 5():53-65. PubMed ID: 21603258
[TBL] [Abstract][Full Text] [Related]
19. Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.
Dranitsaris G; Yu B; Wang L; Sun W; Zhou Y; King J; Kaura S; Zhang A; Yuan P
J Oncol Pharm Pract; 2016 Apr; 22(2):205-11. PubMed ID: 25316611
[TBL] [Abstract][Full Text] [Related]
20. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Bondarenko I; Paluch-Shimon S; Wardley A; Merot JL; du Toit Y; Easton V; Lindegger N; Miles D;
Ann Oncol; 2019 May; 30(5):766-773. PubMed ID: 30796821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
